Literature DB >> 3393780

Twelve-year experience with chemotherapy in adult metastatic renal cell carcinoma at the Institut Gustave-Roussy.

J P Droz1, C Theodore, M Ghosn, H Lupera, G Piot, A De Forges, M Klink, J Rouesse, J L Amiel.   

Abstract

One hundred fifty-three adult patients with metastatic renal carcinoma were treated over a 12-year period. Five successive chemotherapeutic protocols were used: vincristine or teniposide plus CCNU, elliptinium weekly or monthly, ifosfamide, and lastly, a multidrug regimen with adriamycin, vindesine, cyclophosphamide, cisplatinum, and dacarbazine. Results obtained with these different consecutive protocols were very disappointing with only ten (7%) objective responses encountered.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3393780

Source DB:  PubMed          Journal:  Semin Surg Oncol        ISSN： 1098-2388


  4 in total

1.  Phase II study of fotemustine as second-line treatment after failure of immunotherapy in metastatic renal cell carcinoma.

Authors:  C Lasset; Y Merrouche; S Negrier; P Rebattu; J Berille; J P Bizzari; F Chauvin; T Philip
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

2.  Phase II trial of LY 186641 in advanced renal cancer.

Authors:  M Mahjoubi; J Kattan; M Bonnay; H Schmitt; J P Droz
Journal:  Invest New Drugs       Date:  1993-11       Impact factor: 3.850

3.  Intravenous interleukin-2 in patients over 65 with metastatic renal carcinoma.

Authors:  S Négrier; A Mercatello; M Bret; P Thiesse; J Y Blay; B Coronel; Y Merrouche; R Oskam; C R Franks; M Clavel
Journal:  Br J Cancer       Date:  1992-05       Impact factor: 7.640

4.  Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients.

Authors:  T Philip; S Negrier; C Lasset; B Coronel; M Bret; J Y Blay; Y Merrouche; C Carrie; P Kaemmerlen; F Chauvin
Journal:  Br J Cancer       Date:  1993-11       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.